← All trials
NCT05947890
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 15, 2024
- Primary completion
- Nov 30, 2024
- Completion date
- Nov 30, 2024
- First posted
- Jul 17, 2023
- Last posted
- Sep 21, 2023
- Enrollment
- 276
- Arms / groups
- 12 / —
- Source
- AACT · ctgov ingestion
Sponsors
- HIV Vaccine Trials NetworkLead sponsor
- Biofabri, S.LCollaborator
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- South African Tuberculosis Vaccine Initiative (SATVI)Study chair
- South African Tuberculosis Vaccine Initiative (SATVI)Official
- Africa Health Research InstituteOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.